Skip to content

Placing External Ventricular Drains Using Assistive Augmented Reality or Image-Based Localization

Placing External Ventricular Drains Using Assistive Augmented Reality or Image-Based Localization: A Randomized Controlled Clinical Trial (PEARL)

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07042048
Acronym
PEARL
Enrollment
50
Registered
2025-06-27
Start date
2025-07-01
Completion date
2026-03-31
Last updated
2025-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICH - Intracerebral Hemorrhage, IVH- Intraventricular Hemorrhage, TBI Traumatic Brain Injury

Keywords

EVD, Augmented Reality, TBI, ICH, Image Guidance

Brief summary

The goal of this clinical trial is to assess if EVD placement using augmented reality is non inferior to image-guidance systems for assistance in adult patients needing an EVD for spontaneous ICH with IVH or severe TBI. The main question it aims to answer is: Can EVDs be placed successfully with at least equal safety and efficacy using augmented reality devices in comparison to using standard image-guidance techniques?

Interventions

DEVICEEVD placement - image-guidance assisted

During EVD placement, an image-guided noninvasive systems will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of image-guidance system occurs once during initial EVD placement in this trial.

DEVICEEVD placement - AR assisted

During EVD placement, an AR system will be used to assist the operator for EVD catheter tip navigation through a burr hole opening. The use of AR occurs once during initial EVD placement in this trial.

Sponsors

The Cooper Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adult patient at time of screening * diagnosis of spontaneous ICH with IVH with severe TBI * Meet one or more of the following clinical or radiographic criteria: Tissue swelling on imaging Dysmorphic ventricles on imaging Midline shift \>2mm on imaging Mass effect on imaging Evans Index \<0.3 on imaging Glasgow Coma Scale 3-8 * admitted to Cooper University Health * requires an EVD

Exclusion criteria

* Other concomitant intracranial pathology (e.g., tumor, tumor-related edema/hemorrhage, congenital condition, etc.) * Concurrent participation in another research protocol for investigation of an experimental therapy * Known or suspected inability to adhere to study protocol or protocol requirements, as per the discretion of the investigator

Design outcomes

Primary

MeasureTime frameDescription
Successful EVD catheter placementDuring procedurePost-procedural non-contrast head CT will be reviewed by masked assessor to evaluate success of EVD placement per the Kakarla grading system. This grading system classifies catheter positioning into three grades based on postoperative imaging. Grade 1 indicates optimal placement in the ipsilateral frontal horn or third ventricle for effective drainage. Grade 2 represents functional but non-ideal placement in the contralateral ventricle or non-eloquent cortex. Grade 3 denotes suboptimal placement in eloquent cortex or non-target spaces, potentially leading to complications. Thus, a higher score means a worse outcome.
rate of complication during placementDuring procedure

Secondary

MeasureTime frame
rate of AR or Stealth overlay failures on first tryDuring procedure
rate of EVD failurefrom placement to removal of EVD and assessed up to two weeks after
EVD dislodgment of occlusionfrom placement to removal of EVD and assessed up to two weeks after
rate of catheter tip dispositionsDuring procedure
rate of EVD associated hemorrhagefrom placement to removal of EVD and assessed up to two weeks after
rate if EVD-associated infectionfrom placement to removal of EVD and assessed up to two weeks after
rate of EVD replacement or revisionDuring procedure
number of passes for placementDuring procedure

Countries

United States

Contacts

Primary ContactCorey Mossop, MD
mossop-corey@cooperhealth.edu856-342-2000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026